Carvedilol

Carvedilol is a medicine taken by mouth that the FDA label describes as an alpha-/beta-adrenergic blocking agent. The label read, for Coreg, lists three uses: mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, to increase survival and reduce the risk of hospitalization; reducing cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and whose left ventricular ejection fraction is 40% or less, with or without symptoms of heart failure; and essential hypertension.

Also called Coreg

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 20352; UNII 0K47UL67F2. MeSH descriptor D000077261 is Carvedilol. Class: beta-Adrenergic Blocker (FDA established pharmacologic class, RxClass). The label read is the Waylis Therapeutics LLC label for COREG (carvedilol), application NDA020297, effective 2026-07-31 in openFDA. Coreg CR (carvedilol phosphate extended-release capsules) has its own label, which was not read. This page records label indications and the class only: no trial result and no dose is given.

Trials at a glance

The figures count the 10 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
10
Phase 3 or 4
10
Recruiting
3
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseRecruitingActive, not recruitingCompletedUnknown statusAll statuses
Phase 310102
Phase 421238
All phases313310

Conditions these trials study

And 4 more.

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

And 5 more.

About this drug

Level
Substance
Mechanism
Not reported

Claims and evidence

Context People for whom the US label of carvedilol (Coreg) lists an indication: chronic heart failure, survivors of the acute phase of a myocardial infarction whose left ventricular ejection fraction is 40% or less, essential hypertension

Recipient
Recipient not specified
Population
Patients described in the indications section of the label. The label does not state an age range in the passages read.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the label passages read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 3 inclusion criteria; exclusion criteria not stated
Included
  • Patients with mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin
  • Clinically stable patients who have survived the acute phase of a myocardial infarction and whose left ventricular ejection fraction is 40% or less, with or without symptomatic heart failure
  • Patients with essential hypertension
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of COREG (carvedilol), in the Waylis Therapeutics LLC version dated 2026-07-31 in openFDA, lists the medicine for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin; for reducing cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and whose left ventricular ejection fraction is 40% or less, with or without symptomatic heart failure; and for the management of essential hypertension.

    Applies to Recipient not specified People for whom the US label of carvedilol (Coreg) lists an indication: chronic heart failure, survivors of the acute phase of a myocardial infarction whose left ventricular ejection fraction is 40% or less, essential hypertension

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-08
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for COREG (carvedilol), Waylis Therapeutics LLC label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 07c619c6-4a0c-445e-94fa-664a54f68a39 (manufacturer Waylis Therapeutics LLC, application NDA020297), returned on 2026-11-08. The label text is dated 2026-07-31 (effective_time). Other openFDA records of carvedilol labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1. INDICATIONS AND USAGE
      How it applies
      The label sentences that give the indications named in the statement, each quoted in the research quote table.
      Retrieved
      Source effective date
      2026-07-31
      Source state
      Current
      Version fingerprint
      654e7c2cc0766a1ae7b9072a509447d9ba3519185a297787af7f8e5f1f3b2741
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-08, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for COREG (carvedilol), Waylis Therapeutics LLC label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 07c619c6-4a0c-445e-94fa-664a54f68a39 (manufacturer Waylis Therapeutics LLC, application NDA020297), returned on 2026-11-08. The label text is dated 2026-07-31 (effective_time). Other openFDA records of carvedilol labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260731.
      Retrieved
      Source effective date
      2026-07-31
      Source state
      Current
      Version fingerprint
      654e7c2cc0766a1ae7b9072a509447d9ba3519185a297787af7f8e5f1f3b2741
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-08, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

FDA label

The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.

COREG

No label from the application holder was found in the openFDA label dataset for application NDA020297. This page does not show another labeler's label in its place.

COREG CR

No label from the application holder was found in the openFDA label dataset for application NDA022012. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA020297 COREG
  2. Supplemental approval NDA020297 COREG
  3. Supplemental approval NDA020297 COREG
  4. Supplemental approval NDA020297 COREG
  5. Supplemental approval NDA020297 COREG
  6. Supplemental approval NDA020297 COREG
  7. Approval NDA022012 COREG CR
  8. Supplemental approval NDA020297 COREG

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 2

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 6 efficacy supplement approvals on record.

    ProductNDA020297

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA022012

Registry trials 10

Record details

Record id
cardio:carvedilol
Content hash
263314c1f56a704cd2b19b752ba8aae69e48e764c5649b869b574116e50ea0ad